title: Poorly differentiated thyroid carcinoma: a cytologic-histologic review.
abstract: The term poorly differentiated thyroid carcinoma (PDTC) was first proposed in the 1980s, but it was not definitively recognized as a distinct pathologic entity until the most recent classification of endocrine tumors by the World Health Organization in 2004. More recently, as a result of discussions in Turin, Italy, in 2006, diagnostic criteria were made more specific by a consensus of expert thyroid pathologists. The histologic and cytologic aspects are detailed with particular attention to key features helpful in the diagnosis of PDTC, both in surgical pathology and in cytology-based studies. Histologically, insular, solid, and/or trabecular architecture, along with at least one of the following: convoluted nuclei, mitotic activity (>3/10 HPF), or tumor necrosis, are required for a diagnosis of PDTC. Cytologically, the combination of insular, solid, or trabecular cytoarchitectural pattern, single cells, high nuclear to cytoplasmic (N/C) ratio, and severe crowding are highly suggestive of PDTC. Most PDTCs are immunohistochemically positive for thyroglobulin and thyroid transcription factor 1 (TTF-1), and a subset is also positive for p53. On the molecular level, ras mutations are the most common finding. PDTCs are managed aggressively by total thyroidectomy, I, and in some cases, external beam radiotherapy.
authors.affiliation: Pathologie Clinique, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
authors.forename: Massimo
authors.initials: M
authors.lastname: Bongiovanni
authors.forename: Peter M
authors.initials: PM
authors.lastname: Sadow
authors.forename: William C
authors.initials: WC
authors.lastname: Faquin
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D044963:Biopsy, Fine-Needle; D002277:Carcinoma / Q000145:classification / Q000378:metabolism / Q000473:pathology*; D004268:DNA-Binding Proteins / Q000032:analysis / Q000378:metabolism; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D009154:Mutation; D013954:Thyroglobulin / Q000032:analysis / Q000378:metabolism; D013961:Thyroid Gland / Q000378:metabolism / Q000473:pathology*; D013964:Thyroid Neoplasms / Q000145:classification / Q000378:metabolism / Q000473:pathology*; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000378:metabolism; D018631:ras Proteins / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C504003:TTF1 protein, human; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D013954:Thyroglobulin; D018631:ras Proteins